Viewing Study NCT03194893

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:26 AM
Ignite Modification Date: 2026-05-08 @ 8:32 PM
Study NCT ID: NCT03194893
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-25
First Post: 2017-06-20
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Sponsor: Hoffmann-La Roche
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-small cell lung cancer (NSCLC) View
None Anaplastic lymphoma kinase (ALK) View
None Rearranged during transfection (RET) View
None Alectinib View
None Crizotinib View